RecruitingHeart Failure With Preserved Ejection Fraction (HFpEF)Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)

A Study to Investigate CV Outcomes With Elecoglipron Compared With Placebo in Adult Participants With HFpEF or HFmrEF

Eligible age

18+ yrs

Accepts

All genders

Locations

34 states

Healthy volunteers

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

This is a Phase III, randomized, double-blind, parallel-group, placebo-controlled, multicenter study to investigate CV outcomes with elecoglipron compared with placebo, in adults with heart failure with preserved ejection fraction (HFpEF)/heart failure with mildly reduced ejection fraction (HFmrEF), irrespective of T2DM status, and who are on background dapagliflozin in addition to other background standard of care.

Sponsor: AstraZeneca

You may qualify if…

✓ Left ventricular ejection fraction (LVEF) of \> 40% within 12 months prior to screening.
✓ Structural heart disease evidence.
✓ HF diagnosed with New York Heart Association (NYHA) Class II-IV at the time of screening.

You may not qualify if…

✕ BMI \<25 kg/m² at screening.
✕ Diabetes exclusions:
✕ History of type 1 diabetes.
✕ HbA1c ≥10% at screening.
✕ Currently receiving or anticipated to receive therapeutic intervention for diabetic retinopathy and/or macular edema.
✕ more than 1 episode of severe hypoglycemic event within 180 days prior to screening, or hypoglycemia unawareness/poor recognition.
✕ Renal exclusions:
✕ On a prespecified renal replacement therapy, or eGFR below a prespecified threshold at screening